Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of Mycobacterium Tuberculosis in a High-incidence Community

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2001 Feb 7

PMID 11158121

Citations 64

Authors

A Van Rie

R Warren

I Mshanga

A M Jordaan

G D Van der Spuy

M Richardson

J Simpson

R P Gie

D A Enarson

N Beyers

P D Van Helden

T C Victor

Affiliations

Soon will be listed here.

Abstract

Correct and rapid diagnosis is essential in the management of multidrug-resistant tuberculosis (MDR-TB). In this population-based study of 61 patients with drug-resistant tuberculosis, we evaluated the frequency of mutations and compared the performance of genotypic (mutation analysis by dot blot hybridization) and phenotypic (indirect proportion method) drug resistance tests. Three selected codons (rpoB531, rpoB526, and katG315) allowed identification of 90% of MDR-TB cases. Ninety percent of rifampin, streptomycin, and ethambutol resistance and 75% of isoniazid resistance were detected by screening for six codons: rpoB531, rpoB526, rrs-513, rpsL43, embB306, and katG315. The performance (reproducibility, sensitivity, and specificity) of the genotypic method was superior to that of the routine phenotypic method, with the exception of sensitivity for isoniazid resistance. A commercialized molecular genetic test for a limited number of target loci might be a good alternative for a drug resistance screening test in the context of an MDR "DOTS-plus" strategy.

Citing Articles

Detection of genomic mutations in and genes among multidrug-resistant isolates from Tehran, Iran.

Motavaf B, Keshavarz N, Ghorbanian F, Firuzabadi S, Hosseini F, Zaker Bostanabad S New Microbes New Infect. 2021; 41:100879.

PMID: 34012550 PMC: 8113720. DOI: 10.1016/j.nmni.2021.100879.

Frequency of Codon 306 Mutations in Gene of Resistant to Ethambutol: A Systematic Review and Meta-Analysis.

Mohammadi B, Ramazanzadeh R, Nouri B, Rouhi S Int J Prev Med. 2020; 11:112.

PMID: 33088440 PMC: 7554598. DOI: 10.4103/ijpvm.IJPVM_114_19.

Bridging the gap between policy and practice: a qualitative analysis of providers' field experiences tinkering with directly observed therapy in patients with drug-resistant tuberculosis in Addis Ababa, Ethiopia.

Mussie K, Gradmann C, Manyazewal T BMJ Open. 2020; 10(6):e035272.

PMID: 32554739 PMC: 7304814. DOI: 10.1136/bmjopen-2019-035272.

Frequency of genomic mutations mediating resistance of Mycobacterium tuberculosis isolates to rifampicin in Northern Morocco.

Karimi H, Oudghiri A, En-Nanei L, El Mzibri M, Laglaoui A, Chaoui I Rev Inst Med Trop Sao Paulo. 2020; 62:e37.

PMID: 32520212 PMC: 7274765. DOI: 10.1590/S1678-9946202062037.

Multi-Label Random Forest Model for Tuberculosis Drug Resistance Classification and Mutation Ranking.

Kouchaki S, Yang Y, Lachapelle A, Walker T, Walker A, Peto T Front Microbiol. 2020; 11:667.

PMID: 32390972 PMC: 7188832. DOI: 10.3389/fmicb.2020.00667.

References

Morris S, Bai G, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D . Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis. 1995; 171(4):954-60. DOI: 10.1093/infdis/171.4.954. View

Cockerill 3rd F . Genetic methods for assessing antimicrobial resistance. Antimicrob Agents Chemother. 1999; 43(2):199-212. PMC: 89052. DOI: 10.1128/AAC.43.2.199. View

Farmer P, Kim J . Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ. 1998; 317(7159):671-4. PMC: 1113843. DOI: 10.1136/bmj.317.7159.671. View

Marttila H, Soini H, Eerola E, Vyshnevskaya E, Vyshnevskiy B, Otten T . A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother. 1998; 42(9):2443-5. PMC: 105851. DOI: 10.1128/AAC.42.9.2443. View

Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston M . Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f. View

Nachamkin I, Kang C, Weinstein M . Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect Dis. 1997; 24(5):894-900. DOI: 10.1093/clinids/24.5.894. View

Heifets L, Cangelosi G . Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 1999; 3(7):564-81. View

Williams D, Waguespack C, Eisenach K, Crawford J, Portaels F, Salfinger M . Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994; 38(10):2380-6. PMC: 284748. DOI: 10.1128/AAC.38.10.2380. View

Kapur V, Li L, Iordanescu S, Hamrick M, Wanger A, Kreiswirth B . Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol. 1994; 32(4):1095-8. PMC: 267194. DOI: 10.1128/jcm.32.4.1095-1098.1994. View

10.

Frieden T, SHERMAN L, Maw K, Fujiwara P, Crawford J, Nivin B . A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA. 1996; 276(15):1229-35. View

11.

Alland D, Kalkut G, Moss A, McAdam R, Hahn J, Bosworth W . Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med. 1994; 330(24):1710-6. DOI: 10.1056/NEJM199406163302403. View

12.

van Embden J, Cave M, Crawford J, Dale J, Eisenach K, Gicquel B . Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993; 31(2):406-9. PMC: 262774. DOI: 10.1128/jcm.31.2.406-409.1993. View

13.

Wengenack N, Uhl J, St Amand A, Tomlinson A, Benson L, Naylor S . Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. J Infect Dis. 1997; 176(3):722-7. DOI: 10.1086/514096. View

14.

Pablos-Mendez A, Raviglione M, Laszlo A, Binkin N, Rieder H, Bustreo F . Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998; 338(23):1641-9. DOI: 10.1056/NEJM199806043382301. View

15.

Pozzi G, Meloni M, Iona E, Orru G, Thoresen O, Ricci M . rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol. 1999; 37(4):1197-9. PMC: 88675. DOI: 10.1128/JCM.37.4.1197-1199.1999. View

16.

Ramaswamy S, Musser J . Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 2000; 79(1):3-29. DOI: 10.1054/tuld.1998.0002. View

17.

Weyer K, Groenewald P, Zwarenstein M, Lombard C . Tuberculosis drug resistance in the Western Cape. S Afr Med J. 1995; 85(6):499-504. View

18.

Victor T, Jordaan A, Van Rie A, Van der Spuy G, Richardson M, Van Helden P . Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. Tuber Lung Dis. 2000; 79(6):343-8. DOI: 10.1054/tuld.1999.0222. View

19.

Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B . Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol. 1997; 35(3):719-23. PMC: 229657. DOI: 10.1128/jcm.35.3.719-723.1997. View

20.

Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs Jr W . Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet. 1994; 344(8918):293-8. DOI: 10.1016/s0140-6736(94)91338-2. View